test

Roy S. Herbst MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Thoracic Oncology Program, Yale Cancer Center

Clinical Interests

Lung cancer; Thoracic Oncology; Personalized Cancer Medicine; Clinical Trials for Lung cancer; Tumor profiling; Tumor biomakers


Board Certifications

1997
Medical Oncology, Board Certified

Patient Care Locations

 
roy_herbstfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Lung A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and Stomach A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Lung A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Lung A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE: Phase 1b/2 INvestigation of anti-Notch Antibody Therapy with Cisplatin and Etoposide in Small Cell Lung Carcinoma Safety and Efficacy)

More Clinical Trials...

Edit Profile